Τόμος 1 (1983) – Τεύχος 3 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 1 (1983) – Issue 3 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Steroids in Cancer

Κέντρο Βιολογικών Ερευνών, Εθνικό Ίδρυμα Ερευνών

Michalis N. Alexis

Biological Research Center, National Hellenic Research Foundation, Athens, Greéce

Alexis, M.N.: Steroids in Cancer, Epitheorese Klin. Farmakol. Farmakokinet. 3: 195-206 (1983)

Steroid hormones, hormone-dependency, carcinogenesis

2.         Hannouche N. et al: Estrogen and progesterone receptors in mammery tumors induced in rats by simultaneous administration of 17p-estradiol and progesterone J, Steroid Biochem. 17: 415 (1982)

3.         Black M.M. et al: Family history, oral contraceptive usage and breast cancer. Cancer 51: 2147 (1983)

4.         Osborne Μ.Ρ. et al: The relationship between family history, exposure to exogenous hormones and estrogen receptor protein in breast cancer. Cancer 51: 2134 (1983)

5.         Fishman J. et al: Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle. Cancer Res. 43: 1884 (1983)

6.         Antunes C.M.F. et al: Endometrial cancer and estrogen use: Report of a large case-control study. N. Engl. J. Med. 300: 9 (1979)

7.         Westaby et ah Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 51: 1947 (1983)

8.         Furukawa H. et al: Effect of sex hormones on carcinogenesis in the stomachs of rats. Cancer Res. 42: 5181 (1982)

9.         Nomura A.M.Y. et al: Fecal neutral steroids in two Japanese populations with different colon cancer risks. Cancer Res. 43: 1910 (1983)

10.       Brentani M.M. et al: Steroid receptors in breast angiosarcoma. Cancer 51: 2105 (1983)

11.        Αλέξης M.N. και Σέκερης K.E.: Υποδοχείς Στεροειδών Ορμονών. Μόρια-κλειδιά yta τη Βιοχημεία και Φαρμακολογία των Ορμονικών Στεροειδών. Επιθεώρηση Κλινικής Φαρμακολογίας και φαρμακοκινητικής 1: 5 (1 983)

12.       Folca P.J. et al: Studies with tritium-labelled hexoestrol in advanced breast cancer: Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. Lancet 2: 796 (1961)

13.       Jensen E.V. and Jacobson FI.I.: Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18: 387 (1962)

14.       King R.J.B, et al: J. Endocrinol 32: 139 (1966)

1 5. Mobbs B.G.: J. Endocrinol 36: 409 (1 966)

16.       Me Guire W.L., Carbone P.P., Vollmer E.P. Eds.: Estrogen receptors in human breast cancer. Raven Press N.Y. (1975)

17.       Kauppila A. et al: Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgury, rediotherapy and progestin. Cancer 50: 2157 (1982)

18.       Hull D.F. et al: Multiple estrogen receptor assays in human breast cancer. Cancer Res. 43: 413 (1983)

19.       Rich M.A. et a I: Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res. 38:4296 (1978)

20.      Gorski C.M. et al: Clinical evaluation and pathological grading in relation to other prognostic factors. In: Prognostic Factors in Breast Cancer (Forrest A.P.M. and Kinkier P.B. eds) p. 311. Livingstone Ltd., Edinburgh. (1968)

21.       Bloom H.J.B. and Richardson W.V.: Histological grading and prognosis in breast cancer. Br. J. Cancer 11: 359 (1957)

22.       Samaan N.A. et al: Oestrogen receptor: A prognostic factor in breast cancer. Cancer 47: 554 (1981)

23.       Pegoraro R.J. et ah Cytoplasmic and nuclear estrogen and progesterone receptors in male breast cancer. Cancer Res. 42: 4812 (1982).

24.       Hilf et al: Does estrogen receptor status have prognostic value for recurrence or chemotherapy response in breast cancer. Proc. Am. Assos. Res. Am. Soc. Clin. Oncol 20: 298 (1979)

25.       Mason B.H. et al: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 43: 2985 (1983)

26.       DeWys W.D. et al: A proposed model for the prediction of response to endocrine therapy in breast cancer from the estrogen receptor status of one site and the number of metastatic sites. Cancer Res. 40: 2423 (1980)

27.       Holdaway I.M. et al: Variation in receptor status between primary and metastatic breast cancer. Cancer 52: 479 (1983)

28.      Lippman M.E. et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298: 1223 (1978)

29.       Hoogstraten B. et al: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res. 42: 4788 (1982)

30.      Jensen E.V. et al: Hormone dependency in breast cancer. J. Steroid Biochem. 7: 91 1 (1976)

31.       Jensen E.V. et al: Receptors reconsidered: A 20-year perspective. Recent Progress in Hormone Research 38: 1 (1982)

32.       McGuire W.L. et al: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39: 2934 (1977)

33.       Demanes D.J. et al: Hormones receptors in hepatoblastoma: A demonstration of both estrogen and progesterone receptors. Cancer 50: 1828 (1982)

34.       Danel L. et al: Presence of estrogen binding sites and browth stimulating effect of estadiol in the human myelogenous cell line HL60. Cancer Res. 42:4701 (1982)

35.       Shain S.A. et al: Human prostate androgen receptor quantitation: Effects of temperature on assay parameters. Cancer Res. 42: 4849 (1982)

36.       Galili, U. et al: Metabolic and ultrastructural aspects of the in vivo lysis of chromic lymphocytic leukemia cells by glucocorticoids. Cancer Res. 42: 1433 (1982)

37.       Bloomfield, C.D. et al: In vitro glucocorticoid studies in human lymphoma: Clinical and biologic significance. J. Steroid Biochem. 75:275 (1981)

38.      Nanni P. et al: Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. Cancer 49: 623 (1982)

39.       Costlow M.E. et al: Glucocorticoid receptors in childhood acute lymphocytic leukemia. Cancer Res. 42: 4801 (1982)

40.      Edwards D.P. et al: Estrogen and progesterone receptor proteines in breast cancer. Biochim. Biophys. Acta 560: 457 (1979)

41.       Karlson P. and Sekeris C.E.: Biochemical mechanism of hormone action. Acta Endocrin. 53: 505 (1966)

42.       Jensen E.V. et al: Two-step mechanism of the interaction of estradiol with rat uterus. Proc. Nat. Acad. Sci. 59: 632 (1968)

43.       Bloom E. et al: Nuclear binding of glucocorticoid receptors: Relation between cytosol binding, activation and the biological response. J. Steroid Biochem. 12: 175 (1980)

44.       PayvarF. et al: Purified glucocorticoid receptor binds selectively in vitro to a cloned DNA fragment whose transcription is requlated by glucocorticoid in vivo, Proc. Nat. Acad. Sci. 78: 6628 (1981)

45.       Taylor R.N. and Smith R.G.: Effects of highly purified estrogen receptors on gene transcription in isolated nuclei. Biochemistry 21: 1781 (1982)

46.       Hansen E.R. and Brooks S.C.: Estron receptor formation during the processiong of estradiol-receptor complex in MCF-7 cells. Cancer Res. 42: 1967 (1982)

47.       Braunsberg H. and Hammand K.D.: Methods of steroid receptor calculation: An interlaboratory study. J. Steroid Biochem 11: 1561 (1979)

48.      Kisling S, et al: The existence of specific receptors for glucocorticoids on the plasma membrane of the rat liver. Bioknimiya (English Edition) 44: 1600 (1979)

49.       Muldoon T.G.: Molecular and functional anomalies in the mechanism of the estrogenic action of 4-mercuri-l 7p-estradiol. J. Biol. Chem. 255: 1358 (1980)

50.       Alexis M.N, et al: The distribution and properties of the glucocorticoid receptor from rat brain and pituitary. J. Biol. Chem. 258: 4710 (1983)

51 Eckert R.L and Katzenellenbogen B.S.: Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res. 42: 139 (1982)

52.       Miyabe S. and Harrison R.W.: In vivo activation and nuclear binding of the AtT-20 mouse pituitary tumor cell glucocorticoid receptor. Endocrinology 112:2174 (1983)

53.       Alexis M.N. et ah Activation and changes in the sedimentation properties of rat liver glucocorticoid receptor, J. Steroid Biochem. 18: 655 (1983)

54.       Rousseau G.G. et al. Steroid-induced nuclear binding of glucocorticoid receptors in intact hepatoma cells. J. Mol. Biol. 79: 539 (1973)

55.       Kitraki E. et al. Glucocorticoid receptors in developing rat brain and liver. J. Steroid Bioch, 20: Jan. 1984

56.       Chrousos G.P. al: Primary cortisol resistance in man a glucocorticoid receptor-disease. J. Clin, invest, 69: 1261 (1982)

57.       Stevens J. et al: Immunochemical differences between glucocorticoid receptors from corticoid sensitive and resistant malignant lymphocytes. Cancer Res. 41:134 (1981)

58.       Terakawa et al: Quantitative changes in estrogen receptor produced by chronic DES treatment of two mouse strains differing in suceptibility to Leuding cell tumor induction. J. Steroid Biochem. 16: 643 (1982)

59.       Sibley C.H. and Tomkins G.M.: Isolation of lymphoma cell variants resistant to killing by glucocorticoids. Cell 2:213 (1974)

60.      Mercer W.D. et al: Identification of estrogen receptors in human breast cancer cells by immunofluorescence, Am. J. Clin. Pathol. 70: 330 (1978)

61.       Manz B. et al: Synthesis of a new disulfide affinity adsorbent for purification of human uterine progesterone receptor. Eur.J. Biochem. 128: 249 (1982)

62.       Tsawdaroglou N. et al: Dexamethasone binding proteins in cytosol and nucleus of rat thymocytes. Purification of three receptor proteins. Eur. J. Biochem. 114:305 (1981)

63.       Greene G.L. and Jensen E.V.: Monoclonal antibodies as probes for estrogen receptor detection and characterization. J. Steroid Biochen. 16: 353 (1982)

64.       Westphal H.M. et al: Monoclonal antibodies to the rat liver glucocorticoid receptor. EMBO Journal 1: 1467 (1982)

65.       Papamichail M. et al: The detection of glucocorticoid receptors in breast cancer by immunocytochemical and biochemical methods, int. J. Cancer 29: 147 (1982)

66.       Higgins S.J. and Gehring O: Molecular mechanisms of Steroid hormone action. Advances in Cancer Research 28: 313 (1978)

67.       Eckert R.L and KatreneKenbogen B.S.: Human endometrial cells in primary tissue culture: Modulation of the progesterone receptor level by natural and synthetic estrogens in vivo. J. Clin. Endocrinol. Metab. 52: 699 (1981)

68.      Evans E. et al: Estrogen-receptor-DNA interactions. Difference betwean activation by estrogen and antiestrogen Eur. J. Biochem. 128: 185 (1982)

69.       Eckert R.L. and Katrenellenbogen B.S.: Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. Differences with anti-estrogen and estrogen. J. Biol. Chem. 257: 8440 (1982)

70.       Ciocca D.R. et al: Immunohistochemical detection of an estrogen-regulated protein by monoclonal antibodies. Cancer Res. 42: 4256 (1982)

71.       Capony F. et al: Antibodies to the estrogen induced 52k protein released by human breast cancer cells. Biochem. Biophys. Res. Common. 108: 8 (82)

72.       Ciocca D.R. et al: Distribution of an estrogen induced protein with a molecular weight of 24000 in normal and malignant human tissues and cells. Cancer Res. 43: 1204 (1983)

73.       Ceriani R.L, et al: Circulating human mammary epithelial antigens in breast cancer. Proc. Natl Acad. Set (USA) 79: 5420 (1982)

74.       Huang F.L. and Cho-Chung Y.S.: Alteration in gene expression at the onset of hormone-dependent mammary tumor regression. Cancer Res. 43: 2138 (1983)

75.       Voris B.P. et al: Development of resistance to glucocorticoid hormones during rat thymus cell differentiation: Proteins associated with emergence of the resistant state. Cancer Res. 43: 1236 (1983)

76.       Horwitz K.B. et al: Variant T47D human breast cancer cells with high progesterone-receptor despite estrogen and antiestrogen resistance. Cell 28: 633 (1982)

77.       Yoshida, H. et al: Biological characteristics and estrogen and progesterone receptors in mammary carcinoma induced in male sprague-Dawley rats by a series of intragastric incubations of 7,12-Dimethyl-denz(a)anthracene. Cancer Res. 42: 2434 (1982)

78.       Yoshida, H. et al: Effect of pharmacological doses of estrogen on ovary-independent rat mammary carcinoma containing estrogen and progesterone receptors. Cancer Res. 43: 2311 (1983)

79.       Brandes L.J. and Homonat M.W.: Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to Diethyl-stilbestrol. Cancer Res. 43: 2831 (1983)

80.      Fisher B. et al: The influence of tumor estrogen and progesterone receptor levels on the response to Tamoxifen and chemotherapy in primary breast cancer. J. CUn. Oncol. (1983), in press

81.       Sandbach J. et al: Direct cloning of human breast cancer in soft agar culture. Cancer 50: 1315 (1982)

82.      Friedman H.M. and Gläubiger D.L.: Assessment of In vitro drug sensitivity of human tumor cells using [3Hj Thymidine incorporation in a modified human tumor stem cell assay. Cancer Res. 42: 4683 (1982)

83.      Goldenberg G.J. and Froese E.K.: Drug and hormone sensitivity of estrogen receptor-positive and negative human breast cancer cells in vitro. Cancer Res. 42: 5247 (1982)

84.      Darbe P, et al: Effect of estradiol on human breast cancer cells in culture. Cancer Res. 43: 349 (1983)

85.       Danel L et al: Presence of estrogen binding sites and crowth-stimulating effect of estradiol in the human myelogenous cell line HL60. Cancer Res. 42: 4701 (1982)

86.      Page, M J. et al: Serum regulation of the estrogen responsiveness of the human breast cancer cell line MCF-7. Cancer Res. 43: 1244 (1983)

87.       Leung B.S. et al: Responce to estrogen by the human mammary carcinoma cell line CAMA-1. Cancer Res. 42: 5060 (1982)

88.      McGrath C.M.: Augmentation of the response of normal mammary epithelial cells to estradiol by mammary stroma. Cancer Res. 43: 1355 (1983)

89.      Butler W.B. et al: Steroid stimulation of plasminogen activator production In a human breast cancer cell line (MCF-7). Cancer Res. 43. 1637 (1983)

90.      Wilson E.L. et al: The effects of dexamethesone and tetradecanoyl phorbo: acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood6 1 : 561 (1983)

91.       Leibi H. and Spona J.: Differential stimulation by 17ß-Estradial and synthetic estrogens of progesterone-receptor and of translocation of estrogen receptor in rat pituitary and uterus. Endocrinology 110: 265 (1982)

92.       Coezy et at: Tamoxifen and metobolites in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42: 317 (1982)

93.       Winnecker R.G. and Clark J.H.: Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver. Endocrinology 112: 1910 (1982)

94.       Prost 0. and Adessi G.L.: Estrone and dehydroepiandrosterone sulfatase activities in normal and pathological human endrometrium biopsies. J. CUn. Endocrinol. Metab. 56: 653 (1983)

95.       Jordan V.C. et al: Determination and pharmacology of a new hydroxylated metabolite of Tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 43: 1446 (1983)

96.       Syne J.S. et al: Estrogen binding sites in the nucleus of normal and malignant human tissue: Characteristics of the multiple nuclear binding sites. Cancer Res. 42: 4449 (1982)

97.       Barrack E.R. et al: Subcellular distribution of adrogen receptors in human normal. Benign hyperplastic and malignant prostatic tissues: Characterization of nuclear salt-resistant receptors. Cancer Res. 43: 1107 (1983)

98.      Yammamoto K.R. and Alberts B.: The interaction of estradiol receptor with the genome: An argument for the existence of undetected specific sites. Cell 4: 301 (1975)

99.       Clark J. H. and Peck E.J.: Nuclear retention of receptor-estrogen complex and nuclear acceptor sites. Nature 260:635 (1976)

100.    Rodbard D. et al: Quantitative characterization of hormone receptors. Cancer 46: 2907 (1980)

101.     Panko W.B et al: The presence of a second specific estrogen binding site in human breast cancer. J. Steroid Biochem. 14: 1311 (1981)

102.     Panko W.B. and Clark J.H.: The effect of a second specific estrogen binding site on estrogen receptor quantitation in human breast cancer cytosol. J. SteroidBiochem, 15:383 (1981)

103.     Wagner R.K. and Jungblut P.W.: Quality control in steroid receptor analysis. Cancer 46: 2950 (1980)

104.     Bridges K.G. et al: Influence of surgical techniques on estrogen and progesterone receptor determinations in breast cancer. Cancer 51: 2317 (1983)

105.     Sica V. et al: Effect of chemical perturbation with sodium thiocyanate on receptor-estradiol interaction. A new exchange assay at low temperature. Biochemistry 19:83 (1980)

106.     Jacobs S.R. et al: Cytochemical and competitive protein binding assays for estrogen receptor in breast disease. A comparative study of 62 cases. Cancer 51:1621 (1983)

107.     Chamness G.C. et al: Are histochemical methods for estrogen receptor valid? Histochem. Cytoche’m. 28: 792 (1980)

108.    Shimizu M. et ah PAP immunoperoxidase method demonstrating endogenous estrogen in breast carcinomas. Cancer 52: 486 (1983)

109.     Buell R.H and Tremblay G.:The localization of [3H| – estradiol in estrogen receptor-positive human mammary carcinoma as visualized by thaw-mount autoradiography. Cancer 51: 1625 (1983)

110.     Bayard F. et al: Cytoplasmic and nuclear estradial and progesterone receptors in human endometri um.J, CUn. Endocrin. Metab. 46: 635 (1978)

111.      King R J.B. et al: Regulation of estrogen and progesterone receptor levels in epithelium and stroma from pre-and postmenopausal endometria, J. Steroid Biochem, 16:21 (1982)